Zevra Therapeutics to present at Canaccord Genuity Annual Growth ConferencePUBT·1 day ago, 06:34 AMZVRA+0.29%
10:07 ETZevra Therapeutics (ZVRA) Securities Investigation Notice - Levi & Korsinskyprnewswire·2 days ago, 09:08 AMZVRA+0.29%
Zevra publishes four-year real-world U.S. early access data on MIPLYFFA in Niemann-Pick disease type CPUBT·2 days ago, 06:30 AMZVRA+0.29%
Zevra Therapeutics Announces Publication of Four-Year Real-World Data from U.S. Early Access Program Evaluating MIPLYFFA® (arimoclomol) in Niemann-Pick Disease Type C (NPC) | ZVRA Stock NewsStockTitan·2 days ago, 10:30 PMZVRA+0.29%
ZVRA Investors Have Opportunity to Join Zevra Therapeutics, Inc. Fraud Investigation with SBS LawMorningStar·Jul 27 at 07:56 PMZVRA+0.29%
17:19 ETZevra Therapeutics Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Zevra Therapeutics (ZVRA)prnewswire·Jul 27 at 04:20 PMZVRA+0.29%
This General Motors Analyst Turns Bulish; Here Are Top 5 Upgrades For Mondaybenzinga_article·Jul 27 at 06:23 AMF-C+0.12%F-D0.00%
Zevra Therapeutics (ZVRA) Is Down 25.4% After EMA Rejects Arimoclomol MAA In NPC Re-Examination BidSimplywall·Jul 26 at 08:15 PMZVRA+0.29%
Capital's Great Migration: From a $55B Gaming Buyout to the Hard Tech BoomGlobal Report·Jul 26 at 04:18 AMEA0.00%MRCY-1.81%
The Fringe of the 2026 Market: Where the Real Weirdness HappensGlobal Report·Jul 26 at 04:15 AMMRCY-1.81%LDOS-1.45%
